MỘT CHỈ điểm TIM MẠCH mới điều TRỊ dự PHÒNG BỆNH lý TIM MẠCH DO vữa xơ

MT CH M TIM MCH MI
U TR D PHÒNG BNH LÝ TIM MCH DO V

Huỳnh Văn Minh, Nguyễn Thanh Định







 


ABSTRACT
MYELOPEROXIDASE (MPO)
Myeloperoxidase (MPO) is a leukocyte-derived enzyme that catalyzes the formation of a
number of reactive oxidant species. MPO-derived oxidants contribute to tissue damage during
inflammation. MPO-catalyzed reactions attributed to potentially proatherogenic biological
activities throughout the evolution of cardiovascular disease.
MPO represent attractive targets for both prognostication and therapeutic intervention in the
prophylaxis of atherosclerotic cardiovascular disease.

I. LCH S NGHIÊN CU V MYELOPEROXIDASE
                

 
 

  
 peroxide 50

[1]
protein
heme này, thành công b [4]

 
trong 2000- í
 
[8]. 
 

 

<894

895-1657

> 1657

1.[3]

II. CA MYELOPEROXIDASE

Hình 1. [9].
  
và 

 c.
[9].
III. C TÁC  A MYELOPEROXIDASE
 
      
2
O
2
) và các ion clorua (Cl
-
). Hydrogen
                
leukocyte, xanthine oxidase, uncoupled nitric oxide synthase (NOS), và isoenzymes Nox khác
nhau.  
 
[6].
H
2
O
2
+ Cl

-
+ H
+ MPO
HOCl + H
2
O

Hình 2.  [10]
 

 MPO làm
 













rung
tính bám dính,






bào

Hình 3. b Vasc Biol. 2005;25:1102-1111.)

IV. CU V MYELOPEROXIDASE
Marie-Luise Brennan và cng s



                
Mye


  nhng bnh
nhân không có bng chng v hoi t c myeloperoxidase 
bn d c ln các biu hin bt li mm t phân v 2,
3, và th 4 t l chênh, 2,2 [ tin cy 95% khong 1,1- tin cy 95% khong 2,1-
8,4 tin cy 95% khong 2,0-ng) lúc 6 tháng [2], [8].
Stephan Baldus  
  
                
p= 0,003). 
p= 0,001) [12].

Tertile 1 MPO < 222 ug/L, Tertile 2 MPO 222  350 ug/L, Tertile 3 MPO > 350 ug/L

Hình 4. -
NORFOLK (Baldus và cs., Circulation 2003, 108-14400:5)



 
 [-
124,1] vs 33,5 [6,6-400,2], p = 0,001). 

Mar                
 
 
-


 -1,84; p < 0,001). 

-

-130 mg / dl, HDL-c CRP
2,0 mg/l (OR 1,52 [95% CI 1,21-1,91], 1,59 [95% CI 1,24-2,05], 1,42 [95% CI 1,14-1,77)],
[8].













Hình 5. - Wong và cs. JACC 2009)
0
5
10
15
20
24 hours 72 hours 30 days 6 months
1st tertile
2nd tertile
3rd tertile
CAC 0-9
CAC 10-99

CAC>=100
0.0%
5.0%
10.0%
15.0%
MPO<257pm MPO>=257pm
0.3%
0.9%
3.2%
3.9%
7.1%
14.0%
CVD Events (%)

- 

 

  

     
 
C. 
P = 0,048). 

V. N

 



1. Biasucci LM, Luizzo G, Angiolillo DJ and al (2000), "Infammation and acute coronary
syndromes", Herz, 25 (2), pp. 108-12.
2. Brennan ML, Penn MS, Van Lente F, et al (2003). Prognostic value of myeloperoxidase
in patients with chest pain. N Engl J Med; 349:1595-604.
3. Cavusoglu E et al. (2007), "Usefulness of baseline plasma myeloperoxidase levels as an
independent predictor of myocardial infarction at two years in patients presenting with
acute coronary syndrome", Am J Cardiol, 99, pp. 1364-68.
4. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. (1994), "Myeloperoxidase, acatalyst
for lipoprotein oxidation, is expressed in human atherosclerotic lesions", J Clin Invest,
94, pp. 437- 444.
5. Eiserich JP et al. (2002), "Myeloperoxidase: A leukocyte-derived vascular NO oxidase",
Science, 296, pp. 2391-94.
6. Fu X et al. (2001), "Hypochlorous acid oxygenates the cysteine switch domain of pro-
matrilysin (MMP-7): A mechanism for matrix metalloproteinase activation and
atherosclerotic plaque rupture by myeloperoxidase", J Biol Chem, 276, pp. 41279-87.
7. Khan, Sohail Q. Kelly, Dominic Quinn, Paulene Davies, Joan E.Ng, Leong L. (2007),
"Myeloperoxidase aids prognostication together with NT-BNP in high-risk patients with
acute ST elevation myocardial infarction", Heart, 93(7), pp.826-831
8. Marijn C. Meuwese (2007), "Serum Myeloperoxidase Levels Are Associated With the
Future Risk of Coronary Artery Disease in Apparently Healthy Individuals", J Am Coll
Cardiol,50, pp. 159-65.
9. M Mathy-Hartert et al. (1998), "Purification of myeloperoxidase from equine
polymorphonuclear leucocytes". Can J Vet Res, 62 (2), pp. 127132.
10. Mukherjee AK. (1995), "Prediction of coronary heart disease using risk factor
categories". J Indian Med Assoc 93 (8), pp. 3125.
11. Nicholls SJ and Hazen SL. (2005), "Myeloperoxidase and cardiovascular disease",
Arterioscler Thromb Vasc Biol, 25, pp. 1102-11.
12. R Esporcatte (2005), "Impact of myeloperoxidase dosage in acute coronary syndrome",
Critical Care, 9(Suppl 2), pp. 10.1186, 10.3574.